Sec Form 3 Filing - McKelligon Brian @ Akoya Biosciences, Inc. - 2021-04-20

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person McKelligon Brian 2. Issuer Name and Ticker or Trading Symbol Akoya Biosciences, Inc. [ AKYA] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) President/CEO (Last) (First) (Middle) 100 CAMPUS DRIVE, 6TH FLOOR 3. Date of Earliest Transaction (MM/DD/YY) 04/20/2021 (Street) MARLBOROUGH, MA01752 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price No securities are beneficially owned. 0 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Employee Stock Option (Right to Buy) $ 0.3 ( 1 ) 11/09/2027 Common Stock 353,129 D Employee Stock Option (Right to Buy) $ 0.3 ( 2 ) 11/09/2027 Common Stock 117,709 D Employee Stock Option (Right to Buy) $ 0.44 ( 3 ) 05/02/2029 Common Stock 248,318 D Employee Stock Option (Right to Buy) $ 0.44 ( 2 ) 05/02/2029 Common Stock 82,772 D Employee Stock Option (Right to Buy) $ 16.12 ( 4 ) 03/24/2031 Common Stock 214,592 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other McKelligon Brian 100 CAMPUS DRIVE, 6TH FLOOR MARLBOROUGH, MA01752 X President/CEO Signatures /s/ Brian McKelligon, Joseph Driscoll, Attorney-in-Fact 04/20/2021 Signature of Reporting Person Date

Explanation of Responses:

( 1 )The option vested as to one-fourth of the shares on July 14, 2018 with the remaining shares vesting in 36 equal monthly installments beginning on July 14, 2018, until fully vested, subject to reporting person's continuous employment. ( 2 )Such performance-based option shares were issued in 2017 and 2019, respectively. In 2020, the options vested as performance conditions were determined to have been achieved. ( 3 )The option vested as to one-fourth (1/4) of the shares on September 26, 2019 with the remaining shares vesting in 36 equal monthly installments beginning on September 26, 2019, until fully vested, subject to reporting person's continuous employment. ( 4 )The option shall vest with respect to (1/4) of such shares on March 22, 2022 and the remaining shares shall vest in 36 equal monthly installments beginning on March 22, 2022, until fully vested, subject to reporting person's continuous employment.

Remarks: Exhibit 24.1 Power of Attorney

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.